Everything You Need to Know About XTANDI Prescribing Information
If you or your loved one has been diagnosed with prostate cancer, you may have heard of XTANDI. XTANDI is a prescription medication that is used to treat prostate cancer. It is a type of cancer called castration-resistant prostate cancer (CRPC) that has spread to other parts of the body. If you are a healthcare provider considering XTANDI as a treatment option for your patients, it is crucial that you understand its prescribing information thoroughly.
What is XTANDI and How Does it Work?
XTANDI is an androgen receptor inhibitor. It works by blocking androgens, which are hormones that stimulate prostate cancer growth. The active ingredient in XTANDI is enzalutamide. When taken as prescribed, XTANDI prevents androgen receptors from interacting with androgen hormones. This means that the cancerous cells do not receive the signal to divide and grow, which can slow down or stop the progression of the disease.
What is the Recommended Dosage?
XTANDI is available in capsules of 40 mg strength. The recommended dose for XTANDI is 160 mg (four capsules of 40 mg) once daily. It is taken orally with or without food at approximately the same time every day. Capsules should be swallowed whole and not opened, crushed, or chewed.
It is important to note that dose adjustments may be necessary based on individual patient factors such as age, weight, and overall health status. Healthcare providers should assess patients throughout the treatment course and adjust the dose as necessary.
What Are the Possible Side Effects?
Like with any medication, XTANDI may cause side effects. Common side effects include fatigue, hot flashes, hypertension, and joint pain. More severe side effects may include seizures, brain injury, and allergic reactions. Patients should report any new or worsening symptoms to their healthcare provider immediately. Healthcare providers should monitor patients for adverse reactions throughout the treatment course.
What are the Contraindications and Precautions?
XTANDI is not recommended for use in women and children since it can cause fetal harm when administered to a pregnant woman. It is also contraindicated in patients with hypersensitivity to the active ingredient, enzalutamide.
XTANDI should be used with caution in patients with a history of seizures, brain injury, and cardiovascular disease. Patients with a risk of fractures should also be monitored closely because XTANDI may increase the risk of bone fractures.
Conclusion
XTANDI is a potent medication that has shown promising results in the treatment of prostate cancer. However, healthcare providers must be well-versed with its prescribing information, side effects, and dosing to provide optimal care to their patients. As with any medication, the benefits must outweigh the risks, and patients should be closely monitored for adverse reactions. With adequate knowledge, healthcare providers can make informed decisions and work towards improving the lives of prostate cancer patients.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)
Speech tips:
Please note that any statements involving politics will not be approved.